Drug factory · FDA FEI 3004202226

Wuhan Biocause Pharmaceutical Development Co., Ltd

Building 1, Hi-Tech Industrial Zone, Zhuankou Economic Technology Development Area, Wuhan, China

China: 1

Problems found, fixed voluntarily at FDA's last inspection, Mar 14, 2025.

Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.

5 drug inspections on record since 2010: 0 with no problems, 5 with problems fixed voluntarily, 0 with FDA action.

What it does, for whom

DrugRoleForNDC
MilrinoneMakes the active ingredient Hospira, Inc. 0409-1983, 0409-2045

FDA inspection history

EndedResultProgramProblems noted
Mar 14, 2025Problems found, fixed voluntarilyDrug Quality Assurance—
Aug 24, 2018Problems found, fixed voluntarilyDrug Quality Assurance—
Jul 22, 2016Problems found, fixed voluntarilyDrug Quality Assurance—
Feb 28, 2014Problems found, fixed voluntarilyDrug Quality Assurance—
Jul 23, 2010Problems found, fixed voluntarilyDrug Quality Assurance—

Registered with FDA for: api manufacture.